Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
The financial success of Covid-19 vaccines for pharma companies is not as straightforward as expected. Despite initial gains for companies like Pfizer and Moderna, the long-term impact on stock prices raises questions about the profitability of vaccine development. Analysts warn that future pandemics may see similar trends, with companies prioritizing public health over financial gains.
Moderna Stock Pops as New Covid-19 Vaccine Shows Positive Results https://t.co/NtrJL7Wmxw
Moderna’s stock rallies after new improved COVID vaccine produced positive trial results https://t.co/I4lSOOL8jg
It's been four years since Covid-19 emerged. Who are the winners and losers of the vaccine race? @matthewherper brings you a company-by-company analysis. https://t.co/QBLo4JrBJo
